openPR Logo
Press release

Community-Acquired Bacterial Pneumonia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Johnson & Johnson, Pfizer Inc., Dainippon

04-19-2024 03:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Community-Acquired Bacterial Pneumonia Market is Expected

The Community-Acquired Bacterial Pneumonia Market Forecast report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the 7MM.
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Community-Acquired Bacterial Pneumonia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Community-Acquired Bacterial Pneumonia Market Forecast [https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Community-Acquired Bacterial Pneumonia Market Report:

* The Community-Acquired Bacterial Pneumonia market size was valued USD 2,616 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In April 2024, The US Food and Drug Administration (FDA) has granted approval to Basilea Pharmaceutica's Zevtera (ceftobiprole medocaril sodium for injection), an antibiotic designed to address various infections. Zevtera is authorized for use in adults with staphylococcus aureus bloodstream infections (SAB) and acute bacterial skin and skin structure infections (ABSSSI). Additionally, it is indicated for the treatment of community-acquired bacterial pneumonia (CABP) in both adult and pediatric patients aged three months and older.
* CAP continues to be a major source of morbidity and mortality in the US, affecting 649 to 847 persons per 100,000 people and leading to over 1.6 million hospital admissions annually. More than 5 million new cases of CAP are diagnosed each year in the United States; 80% of these cases receive outpatient care with a death rate of less than 1%, and 20% receive inpatient care with a mortality rate of 12% to 40% (Sattar & Sharma, 2021)
* Males had a greater incidence of CAP than females did (15.56; 95% CI, 13.90e17.43) versus 9.11 (7.87e10.55) per 10,000 people; p 0.0001. Males had greater incidence rates than females did (p 0.0001), and they rose with age
* DelveInsight calculated that there were 6,886,685 incident cases of community-acquired bacterial pneumonia (CABP) in the 7MM people
* Germany had the most Community-Acquired Bacterial Pneumonia (CABP) incident instances among the EU5 nations, with 568,953 cases in 2019
* Key Community-Acquired Bacterial Pneumonia Companies: Paratek Pharmaceuticals, Forest Laboratories, Melinta Therapeutics, Inc., Chia Tai Tianqing Pharma, Nabriva Therapeutics, Biotest, ACM, AstraZeneca, Eagle Pharma, Cubist Pharma, Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica, and others
* Key Community-Acquired Bacterial Pneumonia Therapies: Omadacycline, Ceftaroline, Delafloxacin, Faropenem, lefamulin, Omadacycline, BT086, Nafithromycin, Ceftaroline fosamil, tigecycline, CAL02, daptomycin, Levofloxacin, and others
* The Community-Acquired Bacterial Pneumonia epidemiology based on gender analyzed that Male ratio is more compare to Female ratio in the case of Community-Acquired Bacterial Pneumonia (CABP)
* The Community-Acquired Bacterial Pneumonia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Community-Acquired Bacterial Pneumonia pipeline products will significantly revolutionize the Community-Acquired Bacterial Pneumonia market dynamics.

Community-Acquired Bacterial Pneumonia Overview

Community-Acquired Bacterial Pneumonia (CABP) is a type of pneumonia that occurs when bacteria infect the lungs and cause inflammation in individuals who have not recently been hospitalized or resided in long-term care facilities. It is one of the most common types of pneumonia and can be caused by various bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, Legionella pneumophila, and others.

Get a Free sample for the Community-Acquired Bacterial Pneumonia Market Report

https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market [https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Community-Acquired Bacterial Pneumonia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Community-Acquired Bacterial Pneumonia Epidemiology Segmentation:

The Community-Acquired Bacterial Pneumonia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of Community-Acquired Bacterial Pneumonia
* Prevalent Cases of Community-Acquired Bacterial Pneumonia by severity
* Gender-specific Prevalence of Community-Acquired Bacterial Pneumonia
* Diagnosed Cases of Episodic and Chronic Community-Acquired Bacterial Pneumonia

Download the report to understand which factors are driving Community-Acquired Bacterial Pneumonia epidemiology trends @ Community-Acquired Bacterial Pneumonia Epidemiology Forecast [https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Community-Acquired Bacterial Pneumonia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Community-Acquired Bacterial Pneumonia market or expected to get launched during the study period. The analysis covers Community-Acquired Bacterial Pneumonia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Community-Acquired Bacterial Pneumonia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Community-Acquired Bacterial Pneumonia Therapies and Key Companies

* Omadacycline: Paratek Pharmaceuticals
* Ceftaroline: Forest Laboratories
* Delafloxacin: Melinta Therapeutics, Inc.
* Faropenem: Chia Tai Tianqing Pharma
* lefamulin: Nabriva Therapeutics
* Omadacycline: Paratek Pharma
* BT086: Biotest
* Nafithromycin: ACM
* Ceftaroline fosamil: AstraZeneca
* tigecycline: Pfizer
* CAL02: Eagle Pharma
* daptomycin: Cubist Pharma
* Levofloxacin: Johnson & Johnson

Discover more about therapies set to grab major Community-Acquired Bacterial Pneumonia market share @ Community-Acquired Bacterial Pneumonia Treatment Market [https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Community-Acquired Bacterial Pneumonia Market Report

* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Community-Acquired Bacterial Pneumonia Companies: Paratek Pharmaceuticals, Forest Laboratories, Melinta Therapeutics, Inc., Chia Tai Tianqing Pharma, Nabriva Therapeutics, Biotest, ACM, AstraZeneca, Eagle Pharma, Cubist Pharma, Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica, and others
* Key Community-Acquired Bacterial Pneumonia Therapies: Omadacycline, Ceftaroline, Delafloxacin, Faropenem, lefamulin, Omadacycline, BT086, Nafithromycin, Ceftaroline fosamil, tigecycline, CAL02, daptomycin, Levofloxacin, and others
* Community-Acquired Bacterial Pneumonia Therapeutic Assessment: Community-Acquired Bacterial Pneumonia current marketed and Community-Acquired Bacterial Pneumonia emerging therapies
* Community-Acquired Bacterial Pneumonia Market Dynamics: Community-Acquired Bacterial Pneumonia market drivers and Community-Acquired Bacterial Pneumonia market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Community-Acquired Bacterial Pneumonia Unmet Needs, KOL's views, Analyst's views, Community-Acquired Bacterial Pneumonia Market Access and Reimbursement

To know more about Community-Acquired Bacterial Pneumonia companies working in the treatment market, visit @ Community-Acquired Bacterial Pneumonia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/community-acquired-bacterial-pneumonia-cabp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Community-Acquired Bacterial Pneumonia Market Report Introduction

2. Executive Summary for Community-Acquired Bacterial Pneumonia

3. SWOT analysis of Community-Acquired Bacterial Pneumonia

4. Community-Acquired Bacterial Pneumonia Patient Share (%) Overview at a Glance

5. Community-Acquired Bacterial Pneumonia Market Overview at a Glance

6. Community-Acquired Bacterial Pneumonia Disease Background and Overview

7. Community-Acquired Bacterial Pneumonia Epidemiology and Patient Population

8. Country-Specific Patient Population of Community-Acquired Bacterial Pneumonia

9. Community-Acquired Bacterial Pneumonia Current Treatment and Medical Practices

10. Community-Acquired Bacterial Pneumonia Unmet Needs

11. Community-Acquired Bacterial Pneumonia Emerging Therapies

12. Community-Acquired Bacterial Pneumonia Market Outlook

13. Country-Wise Community-Acquired Bacterial Pneumonia Market Analysis (2019-2032)

14. Community-Acquired Bacterial Pneumonia Market Access and Reimbursement of Therapies

15. Community-Acquired Bacterial Pneumonia Market Drivers

16. Community-Acquired Bacterial Pneumonia Market Barriers

17. Community-Acquired Bacterial Pneumonia Appendix

18. Community-Acquired Bacterial Pneumonia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=communityacquired-bacterial-pneumonia-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-states-delveinsight-johnson-johnson-pfizer-inc-dainippon]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Community-Acquired Bacterial Pneumonia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Johnson & Johnson, Pfizer Inc., Dainippon here

News-ID: 3470461 • Views:

More Releases from ABNewswire

Four Stocks Shaping the Future of Finance (ATHR,FDS,TRI,NDAQ)
Four Stocks Shaping the Future of Finance (ATHR,FDS,TRI,NDAQ)
The financial information economy has quietly become one of the most durable growth stories in markets. Industry revenues climbed from $33 billion in 2019 to $42 billion in 2024 and are projected to grow 7% annually through 2030, according to Burton-Taylor International Consulting. The financial information economy has quietly become one of the most durable growth stories in markets. Industry revenues climbed from $33 billion in 2019 to $42 billion in
Secure Z100 Jingle Ball MSG Seats Fast with Promo Code CITY10: Dec 12, 2025 at CapitalCityTickets.com
Secure Z100 Jingle Ball MSG Seats Fast with Promo Code CITY10: Dec 12, 2025 at C …
Grab your Z100 Jingle Ball tickets at Madison Square Garden for Dec 12, 2025, fast with CapitalCityTickets.com! Use promo code CITY10 to save instantly. Don't miss performances from top artists, festive vibes, and unforgettable holiday music. Secure the best seats online today and enjoy an epic night of live entertainment at one of New York City's most iconic venues. The Z100 Jingle Ball is back, lighting up Madison Square Garden (MSG)
Cheapest Knicks Tickets Basketball Tickets Online - Best Prices Available with Promo Code CITY10 at CapitalCityTickets.com
Cheapest Knicks Tickets Basketball Tickets Online - Best Prices Available with P …
Get your New York Knicks tickets online at CapitalCityTickets.com and score the cheapest prices with promo code CITY10. Whether you want courtside action or upper-level seats at Madison Square Garden, fans can enjoy NBA games without overspending. Don't miss live basketball excitement featuring Julius Randle, RJ Barrett, and the Knicks - buy your tickets today for every home game this season. The 2025-26 NBA season is here, and New York Knicks
Fiber Optic Cable Market Expected to Reach USD 20.94 Billion by 2030, Driven by High-Speed Internet and 5G Deployments
Fiber Optic Cable Market Expected to Reach USD 20.94 Billion by 2030, Driven by …
Mordor Intelligence has published a new report on the Fiber Optic Cable Market, offering a comprehensive analysis of trends, growth drivers, and future projections. Fiber Optic Cable Market Overview The Fiber Optic Cable Market size is estimated at USD 13.92 billion in 2025, and is expected to reach USD 20.94 billion by 2030, at a CAGR of 10.46% during the forecast period (2025-2030). The market reflects increasing demand for high-speed internet, 5G

All 5 Releases


More Releases for Bacterial

Prominent Bacterial Conjunctivitis Market Trend for 2025: Innovative Eye Drops T …
What Are the Projected Growth and Market Size Trends for the Bacterial Conjunctivitis Market? The bacterial conjunctivitis market has grown steadily, projected to expand from $4.52 billion in 2024 to $4.76 billion in 2025, at a CAGR of 5.3%. Growth factors include rising bacterial infection cases, improved diagnostics, patient education programs, stringent regulatory frameworks, and physician training. The bacterial conjunctivitis market is projected to grow steadily, reaching $5.54 billion by 2029 at
Community-Acquired Bacterial Pneumonia Market
DelveInsight's "Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Community-Acquired Bacterial Pneumonia market report provides current treatment practices, emerging drugs, Community-Acquired Bacterial Pneumonia market share of the individual therapies, and current
Bacterial Conjunctivitis Drugs Market Report 2018: Segmentation by Disease Type …
Global Bacterial Conjunctivitis Drugs market research report provides company profile for Pfizer Inc., Novartis AG, F. Hoffmann-La Roche, Bayer Healthcare, Valeant Pharmaceutical International Inc., Perrigo Company Plc, Akorn Inc., Santen Pharmaceutical Co. Ltd., Allergan Plc. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth
Bacterial Conjunctivitis Drugs Market: Rising Incidence of Ophthalmic Bacterial …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs is extremely fragmented, leading to commensurate competition among players. The entry barriers faced by new players despite having good research and development capabilities, is lack of capital, Transparency Market Research (TMR) states in its new report on the U.S. market for bacterial conjunctivitis drugs. R&D involves huge costs and this limits the production. Mergers and acquisitions and other forms of strategic alliances can
02-07-2017 | Health & Medicine
TMR
Bacterial Conjunctivitis Drugs Market Driven by Rising Incidence of Ophthalmic B …
The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as